Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

Secretary of the Senate Received: Jul 25, 2007

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name: **CAPITOL HEALTH GROUP** 1100 NEW YORK AVENUE, NW SUITE 200M, WASHINGTON, DC 20005-6104 3. Principal place of business (if different from line 2): 4. Contact Name: SHAWN COUGHLIN Telephone: 2022162250 E-mail (optional): shawn@caphg.com Senate ID #: 63713-253 House ID #: 7. Client Name: Self **ABBOTT LABORATORIES** TYPE OF REPORT __ Midyear (January 1 - June 30): 🛛 OR Year End (July 1 - December 31): 🗌 9. Check if this filing amends a previously filed version of this report: 10. Check if this is a Termination Report:

=> Termination Date: 11. No Lobbying Activity: INCOME OR EXPENSES Complete Either Line 12 OR Line 13 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000: -\$10,000 or more: X => Income (nearest \$20,000): 60,000.00 Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000: -\$10,000 or more: => Expenses (nearest \$20,000); 14. Reporting Method. Check box to indicate expense accounting method. See instructions for description of options. Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Page 1

Registrant Name: CAPITOL HEALTH GROUP Client Name: ABBOTT LABORATORIES

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: HCR (one per page)
- 16. Specific lobbying issues:
- S.3 Medicare Prescription Drug Price Negotiation Act of 2007 S.Con.Res.21 Concurrent Resolution on the Budget for Fiscal Year 2008 SCHIP Reauthorization/SGR Reform H.J.Res.20 Revised Continuing Appropriations Resolution, 2007 H.R.4 Medicare Prescription Drug Negotiation Act of 2007 Implementation of DRA (Deficit Reduction Act) Implementation of Medicare Prescription Drug and Modernization Act of 2003

17. House(s) of Congress and Federal agencies contacted: Executive Office of the President (EOP) HOUSE OF REPRESENTATIVES Health & Human Services, Dept of (HHS) SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BROMBERG, MICHAEL
Covered Official Position (if applicable): N/A
Name: COUGHLIN, SHAWN
Covered Official Position (if applicable): N/A
Name: HIGGINS, JENNIFER
Covered Official Position (if applicable): N/A
Name: JENNING, STEVE
Covered Official Position (if applicable): N/A
Name: PELTIER, LAYNA
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Registrant Name: CAPITOL HEALTH GROUP Client Name: ABBOTT LABORATORIES

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: MMM (one per page)
- 16. Specific lobbying issues:
- S.3 Medicare Prescription Drug Price Negotiation Act of 2007 S.Con.Res.21 Concurrent Resolution on the Budget for Fiscal Year 2008 SCHIP Reauthorization/SGR Reform H.J.Res.20 Revised Continuing Appropriations Resolution, 2007 H.R.4 Medicare Prescription Drug Negotiation Act of 2007 Implementation of DRA (Deficit Reduction Act) Implementation of Medicare Prescription Drug and Modernization Act of 2003

17. House(s) of Congress and Federal agencies contacted: Executive Office of the President (EOP) HOUSE OF REPRESENTATIVES Health & Human Services, Dept of (HHS) SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BROMBERG, MICHAEL
Covered Official Position (if applicable): N/A
Name: COUGHLIN, SHAWN
Covered Official Position (if applicable): N/A
Name: HIGGINS, JENNIFER
Covered Official Position (if applicable): N/A
Name: JENNING, STEVE
Covered Official Position (if applicable): N/A
Name: PELTIER, LAYNA
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Signature: ON FILE Date: Jul 25, 2007

Printed Name and Title: SHAWN COUGHLIN, COO & PRINCIPAL -

Registrant Name: CAPITOL HEALTH GROUP Client Name: ABBOTT LABORATORIES

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Jul 25, 2007

Printed Name and Title: -